Studying blood markers in inherited heart-and-nerve amyloidosis
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This study looks for “biomarkers” (measurable signs in blood or other tests) to understand inherited transthyretin amyloidosis, including in people who have not yet developed symptoms. Results may help researchers track the condition earlier and better understand how it changes over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed inherited form of transthyretin amyloidosis with a known TTR gene mutation
- You are either currently affected or a person carrying the TTR mutation who has not developed symptoms yet
- You are 18 years or older
- You can and will sign an informed consent form after understanding the study
- You can attend the study center, complete questionnaires, and do required blood/lab tests
- You can understand the study and follow the study steps; you are willing to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is observing people with amyloidosis or those who carry a specific gene mutation (transthyretin) to learn more about the condition. It does not test any new treatment, but may help researchers understand how the disease affects people.
This study looks at people who carry certain TTR gene variants, which can cause a specific type of heart amyloid buildup. It also includes people with symptoms, to understand how the condition develops and how it may be monitored.
This study looks at tiny particles called extracellular vesicles in the blood of people with a specific type of heart amyloidosis. It aims to find better ways to track the disease and predict outcomes.
This is an observational study (no study drug) for people with transthyretin (TTR)–mediated amyloidosis, including people who carry certain gene changes before symptoms begin. It may help researchers better understand how the disease affects health over time and what to measure in future treatments.
This study looks at how often a specific type of heart condition (wild-type TTR cardiac amyloidosis) occurs in people whose nerve symptoms have no clear cause. The results may help doctors spot this treatable problem earlier when neuropathy is unexplained.
This study looks at how a heart medication (tafamidis) affects amyloid protein levels in the blood over time. It may help doctors understand how well the treatment works for people with a specific type of heart disease caused by amyloid buildup (ATTR-CM).
Hear when a new Hereditary Transthyretin Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.